BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23489211)

  • 1. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
    Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
    J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
    Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
    ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties.
    Incerti M; Russo S; Corrado M; Giorgio C; Ballabeni V; Chiodelli P; Rusnati M; Scalvini L; Callegari D; Castelli R; Vacondio F; Ferlenghi F; Tognolini M; Lodola A
    Eur J Med Chem; 2020 Mar; 189():112083. PubMed ID: 32000051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
    Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
    Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
    Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
    Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
    Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
    ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
    Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
    PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
    Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
    Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
    Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
    Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.
    Jehle J; Staudacher I; Wiedmann F; Schweizer P; Becker R; Katus H; Thomas D
    Br J Pharmacol; 2012 Dec; 167(7):1563-72. PubMed ID: 22845314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.
    Incerti M; Russo S; Callegari D; Pala D; Giorgio C; Zanotti I; Barocelli E; Vicini P; Vacondio F; Rivara S; Castelli R; Tognolini M; Lodola A
    J Med Chem; 2017 Jan; 60(2):787-796. PubMed ID: 28005388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
    Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
    J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
    Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
    J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites.
    Tognolini M; Giorgio C; Hassan Mohamed I; Barocelli E; Calani L; Reynaud E; Dangles O; Borges G; Crozier A; Brighenti F; Del Rio D
    J Agric Food Chem; 2012 Sep; 60(36):8877-84. PubMed ID: 22409255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
    Wykosky J; Debinski W
    Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
    Jannu AK; Puppala ER; Gawali B; Syamprasad NP; Alexander A; Marepally S; Chella N; Gangasani JK; Naidu VGM
    Int J Pharm; 2021 Aug; 605():120819. PubMed ID: 34166727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
    Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
    J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential role for Eph receptor signalling during migration of corneal endothelial cells.
    Walshe J; Richardson NA; Al Abdulsalam NK; Stephenson SA; Harkin DG
    Exp Eye Res; 2018 May; 170():92-100. PubMed ID: 29476773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
    Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.